Lanolin-Based Synthetic Membranes for Transdermal Permeation and Penetration Drug Delivery Assays.
lanolin
penetration
permeation
skin
synthetic membranes
Journal
Membranes
ISSN: 2077-0375
Titre abrégé: Membranes (Basel)
Pays: Switzerland
ID NLM: 101577807
Informations de publication
Date de publication:
15 Jun 2021
15 Jun 2021
Historique:
received:
20
04
2021
revised:
27
05
2021
accepted:
09
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Due to the high similarity in composition and structure between lanolin and human SC lipids, we will work with two models from wool wax. Two types of lanolin were evaluated: one extracted with water and surfactants (WEL) and the other extracted with organic solvents (SEL). Skin permeation and skin penetration studies were performed with two active compounds to study the feasibility of the use of lanolin-based synthetic membranes as models of mammalian skin. Diclofenac sodium and lidocaine were selected as the active compounds considering that they have different chemical natures and different lipophilicities. In the permeation assay with SEL, a better correlation was obtained with the less permeable compound diclofenac sodium. This assay suggests the feasibility of using artificial membranes with SEL as a model for percutaneous absorption studies, even though the lipophilic barrier should be improved. Penetration profiles of the APIs through the SEL and WEL membranes indicated that the two membranes diminish penetration and can be considered good membrane surrogates for skin permeability studies. However, the WEL membranes, with a pH value similar to that of the skin surface, promoted a higher degree of diminution of the permeability of the two drugs, similar to those found for the skin.
Identifiants
pubmed: 34203604
pii: membranes11060444
doi: 10.3390/membranes11060444
pmc: PMC8232266
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Prog Lipid Res. 2003 Jan;42(1):1-36
pubmed: 12467638
J Pharm Pharmacol. 1992 Aug;44(8):640-5
pubmed: 1359086
Eur J Pharm Sci. 2019 Aug 1;136:104945
pubmed: 31163216
Biophys J. 2007 Jan 1;92(1):99-114
pubmed: 17028138
Biochemistry. 1988 May 17;27(10):3725-32
pubmed: 3408722
Adv Drug Deliv Rev. 2013 Feb;65(2):278-94
pubmed: 22750806
Colloids Surf B Biointerfaces. 2020 Apr 17;192:111024
pubmed: 32388029
AAPS PharmSciTech. 2018 May;19(4):1606-1624
pubmed: 29488196
Toxicol In Vitro. 2009 Feb;23(1):1-13
pubmed: 19013230
Skin Pharmacol Physiol. 2006;19(6):296-302
pubmed: 16864974
Curr Med Chem. 2012;19(27):4671-7
pubmed: 22934776
J Control Release. 2001 Aug 10;75(3):283-95
pubmed: 11489316
Int J Pharm. 2019 Feb 10;556:142-149
pubmed: 30529662
J Invest Dermatol. 1987 Jun;88(6):714-8
pubmed: 3585055
Pharmaceutics. 2020 Feb 13;12(2):
pubmed: 32070011
Toxicol In Vitro. 2002 Jun;16(3):299-317
pubmed: 12020604
Clin Dermatol. 2001 Jul-Aug;19(4):387-92
pubmed: 11535378
Skin Pharmacol Physiol. 2018;31(4):198-205
pubmed: 29742517
Pharm Res. 1990 Mar;7(3):230-6
pubmed: 2339094
Pharm Res. 1992 May;9(5):663-9
pubmed: 1608900
Pharmaceutics. 2018 Jun 21;10(3):
pubmed: 29933575
Pharm Res. 2017 Aug;34(8):1728-1740
pubmed: 28540502
Membranes (Basel). 2021 Jan 14;11(1):
pubmed: 33466758
Curr Drug Deliv. 2006 Jan;3(1):95-113
pubmed: 16472099
J Invest Dermatol. 1989 Feb;92(2):251-7
pubmed: 2918233
Adv Drug Deliv Rev. 2007 Sep 30;59(11):1152-61
pubmed: 17889400
Biophys Chem. 2017 May;224:20-31
pubmed: 28363088
Skin Pharmacol Physiol. 2008;21(2):58-74
pubmed: 18187965
J Invest Dermatol. 1975 Jul;65(1):71-84
pubmed: 1097542
Arch Dermatol Res. 2020 Jul;312(5):337-352
pubmed: 31786711
Pharmaceutics. 2019 Jul 02;11(7):
pubmed: 31269690